MTOR and nonpapillary renal cell carcinoma: The primary treatment for early ccRCC is surgery, whereas chemotherapy, targeted therapy (tyrosine kinase inhibitors and mTOR inhibitors), and immunotherapy are the preferred treatments for advanced ccRCC (Vermassen et al., 2017; Atkins and Tannir, 2018; Chen et al., 2019).